Open Access. Powered by Scholars. Published by Universities.®
Department of Pathology, Anatomy, and Cell Biology Faculty Papers
Thomas Jefferson University; Chemoresistance; Gemcitabine; MiR-145; P70S6K1; Pancreatic adenocarcinoma
Articles 1 - 1 of 1
Full-Text Articles in Medical Sciences
Mirna-145 Increases Therapeutic Sensibility To Gemcitabine Treatment Of Pancreatic Adenocarcinoma Cells., Yong Lin, Xin Ge, Yiyang Wen, Zhu-Mei Shi, Qiu-Dan Chen, Min Wang, Ling-Zhi Liu, Bing-Hua Jiang, Yuan Lu
Mirna-145 Increases Therapeutic Sensibility To Gemcitabine Treatment Of Pancreatic Adenocarcinoma Cells., Yong Lin, Xin Ge, Yiyang Wen, Zhu-Mei Shi, Qiu-Dan Chen, Min Wang, Ling-Zhi Liu, Bing-Hua Jiang, Yuan Lu
Department of Pathology, Anatomy, and Cell Biology Faculty Papers
Pancreatic adenocarcinoma is one of the most leading causes of cancer-related deaths worldwide. Although recent advances provide various treatment options, pancreatic adenocarcinoma has poor prognosis due to its late diagnosis and ineffective therapeutic multimodality. Gemcitabine is the effective first-line drug in pancreatic adenocarcinoma treatment. However, gemcitabine chemoresistance of pancreatic adenocarcinoma cells has been a major obstacle for limiting its treatment effect. Our study found that p70S6K1 plays an important role in gemcitabine chemoresistence. MiR-145 is a tumor suppressor which directly targets p70S6K1 for inhibiting its expression in pancreatic adenocarcinoma, providing new therapeutic scheme. Our findings revealed a new mechanism underlying …